Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis

Brain

Volumn 136, Issue 9, 2013, Pages 2888-2903

  Abrahamsson, Sofia V ^a   Angelini, Daniela F ^b   Dubinsky, Amy N ^c   Morel, Esther ^a   Oh, Unsong ^d   Jones, Joanne L ^e   Carassiti, Daniele ^a   Reynolds, Richard ^a   Salvetti, Marco ^f   Calabresi, Peter A ^g   Coles, Alasdair J ^e   Battistini, Luca ^b   Martin, Roland ^h   Burt, Richard K ⁱ   Muraro, Paolo A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

immune regulation; multiple sclerosis; proinflammatory cytokines; stem cells; T cells

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; CD161 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL EXPANSION; CELL PROLIFERATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; WHITE MATTER LESION;

EID: 84883442367     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt182     Document Type: Article

References (52)

1. Adams JC. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Histochem Cytochem 1992; 40: 101457-63.
2. Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009; 113: 1214-23.
3. Annibali V, Ristori G, Angelini DF, Serafini B, Mechelli R, Cannoni S, et al. CD161(high)CD8 + T cells bear pathogenetic potential in multiple sclerosis. Brain 2011; 134 (Pt): 2542-54.
4. Autran B, Leblond V, Sadat-Sowti B, Lefranc E, Got P, Sutton L, et al. A soluble factor released by CD8 + CD57 + lymphocytes from bone marrow transplanted patients inhibits cell-mediated cytolysis. Blood 1991; 77: 102237-41.
5. Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johner C, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011; 479: 7374538-41.
6. Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007; 19: 6652-7.
7. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 155941-6.
8. Billerbeck E, Kang YH, Walker L, Lockstone H, Grafmueller S, Fleming V, et al. Analysis of CD161 expression on human CD8 + T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci USA 2010; 107: 73006-11.
9. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008; 299: 8925-36.
10. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009; 8: 3244-53.
11. Burt RK, Abinun M, Farge-Bancel D, Fassas A, Hiepe F, Havrdova E, et al. Risks of immune system treatments. Science 2010; 328: 5980825-6.
12. Chattopadhyay PK, Betts MR, Price DA, Gostick E, Horton H, Roederer M, et al. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol 2009; 85: 188-97.
13. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 96481502-17.
14. Cossburn MD, Harding K, Ingram G, El-Shanawany T, Heaps A, Pickersgill TP, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 2013; 80: 155-61.
15. Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005; 35: 113332-42.
16. Crawford MP, Yan SX, Ortega SB, Mehta RS, Hewitt RE, Price DA, et al. High prevalence of autoreactive, neuroantigen-specific CD8 + T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004; 103: 114222-31.
17. Darlington PJ, Touil T, Doucet JS, Gaucher D, Zeidan J, Gauchat D, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 2013; 73: 341-54.
18. de Kleer I, Vastert B, Klein M, Teklenburg G, Arkesteijn G, Yung GP, et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4 + CD25 + immune regulatory network. Blood 2006; 107: 41696-702.
19. Dusseaux M, Martin E, Serriari N, Peguillet I, Premel V, Louis D, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 2011; 117: 41250-9.
20. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 9851-62.
21. Hakim FT, Memon SA, Cepeda R, Jones EC, Chow CK, Kasten-Sportes C, et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest 2005; 115: 4930-9.
22. Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011; 134 (Pt): 92755-71.
23. Illes Z, Shimamura M, Newcombe J, Oka N, Yamamura T. Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int Immunol 2004; 16: 2223-30.
24. Jiang W, Chai NR, Maric D, Bielekova B. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol 2011; 187: 2781-90.
25. Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010; 133 (Pt): 82232-47.
26. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13: 101173-5.
27. Kimmig S, Przybylski GK, Schmidt CA, Laurisch K, Mowes B, Radbruch A, et al. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med 2002; 195: 6789-94.
28. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 2012; 491: 7426717-23.
29. Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008; 65: 81044-51.
30. Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, Core M, et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 2010; 11: 8701-8.
31. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130 (Pt): 41089-104.
32. Miyazaki Y, Miyake S, Chiba A, Lantz O, Yamamura T. Mucosalassociated invariant T cells regulate Th1 response in multiple sclerosis. Int Immunol 2011; 23: 9529-35.
33. Mollet L, Sadat-Sowti B, Duntze J, Leblond V, Bergeron F, Calvez V, et al. CD8hi + CD57 + T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. Int Immunol 1998; 10: 3311-23.
34. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317: 5835256-60.
35. Muraro PA, Jacobsen M, Necker A, Nagle JW, Gaber R, Sommer N, et al. Rapid identification of local T cell expansion in inflammatory organ diseases by flow cytometric T cell receptor Vbeta analysis. J Immunol Methods 2000; 246: 131-43.
36. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201: 5805-16.
37. O'Gorman WE, Dooms H, Thorne SH, Kuswanto WF, Simonds EF, Krutzik PO, et al. The initial phase of an immune response functions to activate regulatory T cells. J Immunol 2009; 183: 1332-9.
38. Poggi A, Costa P, Zocchi MR, Moretta L. NKRP1A molecule is involved in transendothelial migration of CD4 + human T lymphocytes. Immunol Lett 1997; 57 (1-3): 121-3.
39. Ratts RB, Lovett-Racke AE, Choy J, Northrop SC, Hussain RZ, Karandikar NJ, et al. CD28-CD57 + T cells predominate in CD8 responses to glatiramer acetate. J Neuroimmunol 2006; 178 (1-2): 117-29.
40. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009; 10: 5514-23.
41. Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler 2012; 18: 6825-34.
42. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, de la Salle H, et al. An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. J Exp Med 1999; 189: 121907-21.
43. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 2003; 422: 6928164-9.
44. Treiner E, Duban L, Moura IC, Hansen T, Gilfillan S, Lantz O. Mucosalassociated invariant T (MAIT) cells: an evolutionarily conserved T cell subset. Microbes Infect 2005; 7: 3552-9.
45. Turtle CJ, Swanson HM, Fujii N, Estey EH, Riddell SR. A distinct subset of self-renewing human memory CD8 + T cells survives cytotoxic chemotherapy. Immunity 2009; 31: 5834-44.
46. Turtle CJ, Delrow J, Joslyn RC, Swanson HM, Basom R, Tabellini L, et al. Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8alpha( + ) semi-invariant T cells. Blood 2011; 118: 102752-62.
47. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172: 1146-55.
48. Vandenbark AA, Huan J, Agotsch M, La Tocha D, Goelz S, Offner H, et al. Interferon-beta-1a treatment increases CD56(bright) natural killer cells and CD4 + CD25 + Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 2009; 215: 125-8.
49. Venken K, Hellings N, Broekmans T, Hensen K, Rummens JL, Stinissen P. Natural naive CD4 + CD25 + CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol 2008; 180: 96411-20.
50. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4 + CD25 + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 7971-9.
51. Walker LJ, Kang YH, Smith MO, Tharmalingham H, Ramamurthy N, Fleming VM, et al. Human MAIT and CD8alphaalpha cells develop from a pool of type-17 precommitted CD8 + T cells. Blood 2012; 119: 2422-33.
52. Zhang L, Bertucci AM, Ramsey-Goldman R, Burt RK, Datta SK. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8 + Treg cells are associated with immunological remission of lupus. J Immunol 2009; 183: 106346-58.